Crysvita (Burosumab-twza)

Crysvita (burosumab-twza) is a fibroblast growth factor 23 (FGF23) blocking antibody used for:

• the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 6 months and older.
• the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients aged 2 years and older.

Recommended Dosage: 

Pediatric XLH (6 months and older): For patients who weigh less than 10 kg, the recommended starting dose regimen is 1 mg/kg of body weight rounded to the nearest 1 mg, administered subcutaneously (SC) every two weeks. For those who weigh 10 kg or greater, the starting dose regimen is 0.8 mg/kg of body weight rounded to the nearest 10 mg, administered every 2 weeks. The minimum starting dose is 10 mg up to a maximum dose of 90 mg.

Adult XLH: The recommended dose regimen is 1 mg/kg body weight rounded to the nearest 10 mg up to a maximum dose of 90 mg administered subcutaneously every 4 weeks.

Pediatric TIO (2 years and older): The recommended starting dose is 0.4 mg/kg of body weight rounded to the nearest 10 mg every 2 weeks. The dose of Crysvita may be increased up to 2 mg/kg not to exceed 180 mg, administered every 2 weeks.

Adult TIO: The recommended starting dose is 0.5 mg/kg subcutaneously (SC) every 4 weeks. Dose may be increased up to 2 mg/kg not to exceed 180 mg, administered every 2 weeks.

• Hypersensitivity reactions (e.g. rash, urticaria) may develop in patients with Crysvita. Discontinue treatment if serious hypersensitivity reactions occur and initiate appropriate medical treatment.
• Increase in serum phosphorus beyond the upper limit of normal may be related to an increased risk of nephrocalcinosis. For patients already taking Burosumab-twza injection, dose interruption and/or dose reduction may be required based on a patient’s serum phosphorus levels.
• Administration of Burosumab-twza may result in local injection site reactions. Stop treatment with Burosumab-twza if severe injection site reactions occur and administer appropriate medical treatment.Injection sites need to be rotated with each injection administered at a different anatomic location (upper thighs, upper arms, buttocks, or any quadrant of abdomen) than the previous injection. Avoid injecting into moles, scars, or areas where the skin is bruised, tender, red, hard, or not intact.

Indian Pharma Network is able to source the CRYSVITA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Crysvita®?

Burosumab-twza is a Generic Name for the trade name drug Crysvita®.

What is the Manufacturer’s Name of Crysvita®?

Crysvita® is manufactured by Kyowa Kirin, Inc.

Is Crysvita® approved by the FDA?

Yes, Crysvita® is approved by the FDA. Date of first approval: April 17, 2018.

What is the dosage and form of Crysvita® supplied?

Crysvita® is supplied as injections: 10 mg/mL, 20 mg/mL, or 30 mg/mL in a single-dose vial for subcutaneous use. 

What are the most common side effects of Crysvita®? 

The most common side effects of Crysvita® are 

pediatric XLH patients: pyrexia, vomiting, injection site reaction, cough, headache, tooth abscess, and dental caries.

adult XLH patients: muscle spasms, back pain, headache, restless legs syndrome, vitamin D decreased, dizziness, constipation, tooth infection, and blood phosphorus increased.

TIO patients: dizziness, tooth abscess, muscle spasms, constipation, injection site reaction, rash, and headache.

How much does Crysvita® cost in India?

The cost of Crysvita in India can vary. To procure this medication legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Crysvita®?

Vials of Crysvita® must be stored in the original carton at 36°F to 46°F (2°C to 8°C). Keep the vials in the original carton to protect them from light until the time of use. Avoid freezing or shaking the vials.

Is it safe to buy Crysvita® online in India?

Yes, one can buy Crysvita online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Crysvita® through legal channels.